By Bhanvi Satija LONDON, July 20 (Reuters) – Novartis investors will look beyond Tuesday's quarterly results for indications about three major drug trial readouts due in the second half of the year
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Advanced chipmaking tool arrives at New York state innovation hub
By Max A. Cherney SAN FRANCISCO, July 21 (Reuters) - The first components of an…
Adani Total Gas Q1 revenue rises 27% YoY to Rs 1910 cr, Volume surges by 13%
Ahmedabad (Gujarat) [India], July 21 (ANI): Adani Total Gas Limited (ATGL) on Tuesday reported a…
Shi Yu Qi survives a scare in China Open, Antonsen crashes out
VIDEO SHOWS: HIGHLIGHTS OF THE FIRST ROUND OF THE CHINA OPEN BADMINTON SHOWS: CHANGZHOU, CHINA…
